Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

1.740 -0.010 (-0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Analyst Expectations for Iovance Biotherapeutics's Future
Via Benzinga
Earnings Preview: Iovance Biotherapeutics
Via Benzinga
Tesla, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers 
Via Benzinga
Why Shares of Iovance Biotherapeutics Jumped Monday
The company's stock rally began on Friday. 
Via The Motley Fool
Over $26M Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
Alteryx, Iovance Biotherapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. Newegg Commerce, Inc. (NASDAQ: NEGG) shares climbed 8.7% to... 
Via Benzinga
Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today
The approval process for the biotech's most advanced pipeline drug program is going quite well, it seems. 
Via The Motley Fool
Personalized Skin Cancer Therapy, Despite FDA Delay: Analysts Show Confidence In Iovance Biotherapeutics Therapy
Thursday, the FDA extended the review period for Iovance Biotherapeutics Inc's (NASDAQ: IOVA) marketing application seeking accelerated approval for lifileucel  
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Where Iovance Biotherapeutics Stands With Analysts
Via Benzinga
Expert Ratings for Iovance Biotherapeutics
Via Benzinga
Why Novonix Shares Are Trading Higher By 27%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 127.8% to $0.1269. The company recently reported second-quarter results. 
Via Benzinga
Nasdaq Down Over 1%; US Industrial Output Rises In August
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% points on Friday. The Dow traded down 0.52% to 34,727.05 while the NASDAQ fell 1.31% to 13,743.78. The... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Volcon Shares Are Trading Lower By 19%; Here Are 20 Stocks Moving Premarket
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares rose 38.7% to $0.1421 in pre-market trading after gaining 10% on Thursday. 
Via Benzinga
Mitek Systems, Arm Holdings And Other Big Stocks Moving Higher In Friday's Pre-Market Session
U.S. stock futures traded mostly higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Shares of Iovance Biotherapeutics Dropped Thursday
The biotech stock's lead therapy is looking at some competition. 
Via The Motley Fool
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi. 
Via Benzinga
Iovance Biotherapeutics Stock Is Down 15%: What's Going On?
Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading lower by 15.8% to $4.58, despite a lack of company-specific news for the session. 
Via Benzinga
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List
Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook. 
Via InvestorPlace
Cathie Wood Continues Iridium Shopping Spree — Ark Invest Buys $3.6M Worth Of Satellite Company's Stock
Via Benzinga
Cathie Wood Buys $3.4M Worth Of Shares In This Payments Software Firm — Also Increases Exposure To Iridium Stock
Via Benzinga
Cathie Wood's Ark Invest Sells Robinhood, Coinbase Shares — Buys $3.5M Worth Of Stock Of This Social Media Company
Via Benzinga
7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick
For investors who choose wisely, profits in healthcare stocks can be spectacular. But the losses can also be dramatic if you choose poorly. 
Via InvestorPlace
Cathie Wood's Ark Invest Continues To Sell Shares Of Warren Buffett-Backed BYD — Coinbase Holdings Trimmed As Well
Via Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday. 
Via Benzinga
Why Iovance Biotherapeutics Stock Is Dropping Tuesday
The company is doing a $150 million public stock offering. 
Via The Motley Fool
DNA Stock Alert: Ginkgo Bioworks Moves Forward With Novo Nordisk Partnership
Ginkgo Bioworks (DNA) stock is on the move Tuesday after the company announced a continued partnership with Novo Nordisk. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback